3050 Spruce Street, St. Louis, MO 63103 USA
Tel: (800) 521-8956 (314) 771-5765 Fax: (800) 325-5052 (314) 771-5757
email: techservice@sial.com sigma-aldrich.com

Product Information

Anti-phospho-YAP1 (pTyr³⁵⁷) produced in rabbit, affinity isolated antibody

Catalog Number Y4645

Anti-phospho-YAP1 (pTyr³⁵⁷) is produced in rabbit using as immunogen a synthetic peptide corresponding to amino acids 351-362 (pTyr³⁵⁷) located in the C-terminal region of human YAP1 (GeneID: 10413), conjugated to KLH. The sequence is identical in chicken YAP1 and highly conserved in mouse YAP1 (single amino acid substitution). The antibody is affinity-purified using the immunizing peptide immobilized on agarose.

Anti-phospho-YAP1 (pTyr³⁵⁷) specifically recognizes human phospho-YAP1 (pTyr³⁵⁷) by immunoblotting (~65 kDa) and immunofluorescence. Staining of the phospho-YAP1 (pTyr³⁵⁷) band in immunoblotting is specifically inhibited by the immunizing peptide. No inhibition with the unmodified peptide is observed.

YAP1 (Yes-associated protein 1, 65 kDa, YAP, YAP2, YAP65) is a modular adapter protein with multiple protein interaction domains that was originally identified based on its interaction with Src-family tyrosine kinase c-Yes. YAP1 plays an important role as a transcription co-activator in regulating gene expression through direct association with a wide range of transcription factors, including Runx2 and PPARy. 2 In addition to a SH3-binding motif, YAP1 contains a proline-rich amino terminus, a WW domain, a coiled-coil and a PDZ-binding motif at the extreme C-terminus, YAP1 binds to p73 through its WW domain and the PPPY motif of p73. This interaction is required for the ability of YAP1 to co-activate p73-responsive genes. 3 YAP1 has been recently reported to be phosphorylated by c-Abl tyrosine kinase at Tyr³⁵⁷. In response to DNA damage YAP1 translocates to the nucleus in a p73-dependent manner. In the nucleus, it promotes p73-dependent apoptosis through the specific and selective co-activation of p53AIP1, an apoptotic p73 target gene. ² YAP1 has been shown to stabilize p73 by preventing Itch-mediated ubiquitination of p73.5

YAP1 also contains a 14-3-3 interacting motif. Upon phosphorylation by Akt at Ser¹²⁷, 14-3-3 is recruited and promotes YAP1 localization to the cytoplasm, resulting in loss of co-activator function in the nucleus.⁶ Inhibition of Akt potentiates the nuclear re-localization of YAP1 to induce apoptosis by p73.⁷

Reagent

Supplied as a solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide as a preservative.

Antibody concentration: ~1.5 mg/mL

Precautions and Disclaimer

This product is for R&D use only, not for drug, household, or other uses. Please consult the Material Safety Data Sheet for information regarding hazards and safe handling practices.

Storage/Stability

For continuous use, store at 2-8 °C for up to one month. For extended storage, freeze in working aliquots. Repeated freezing and thawing, or storage in "frost-free" freezers, is not recommended. If slight turbidity occurs upon prolonged storage, clarify the solution by centrifugation before use. Working dilutions should be discarded if not used within 12 hours.

Product Profile

Immunoblotting: a working concentration of 0.5-1 $\mu g/mL$ is recommended using HEK-293T cells co-transfected with human YAP1 and human c-Abl.

Indirect immunofluorescence: a working concentration of 5-10 μ g/mL is recommended using using HEK-293T cells co-transfected with human YAP1 and c-Abl.

Note: In order to obtain the best results using various techniques and preparations, we recommend determining the optimal working dilutions by titration.

References

- 1. Sudol, M., Oncogene, 9, 2145-2152 (1994).
- 2. Hong, J-H, Yaffe, M.B., *Cell Cycle*, **5**, 176-179 (2006).
- 3. Strano, S., et al., *J. Biol. Chem.*, **276**, 15165-15173 (2001).
- 4. Levy, D., et al., Mol. Cell, 29, 350-361 (2008).
- 5. Levy, D., et al., *Cell Death Differ.*, **14**, 743-751 (2007).
- 6. Basu, S., et al., Mol. Cell, 11, 11-23 (2003).
- 7. Strano, S., et al., Mol. Cell, 18, 447-459 (2005).

ER,KAA,PHC 04/08-1